Ipsen is outgrowing its guidance. Somatuline generics are the next test

The technology

Ipsen is a specialty pharmaceutical company, not a single-platform biotech. It sells drugs in three units: oncology, rare disease and neuroscience. Its best-known products include Somatuline (lanreotide), which faces generic entry, Dysport, a botulinum toxin, and Iqirvo (elafibranor) for primary biliary cholangitis.

The pipeline is a mix of label expansions and acquired drugs. Dysport met phase 3 endpoints in episodic and chronic migraine. Iqirvo's ELSPIRE study showed 85% ALP normalization versus 23% on placebo in patients with milder biochemical disease. Navtemadlin, an oral MDM2 inhibitor bought with Kartos, is in phase 3 as an add-on to ruxolitinib in myelofibrosis. Potravitug, from Memo, is an antibody against BK virus kidney damage after transplant. Corabotase is a recombinant neurotoxin in phase 2 and phase 3.

The odds

Label expansions carry lower risk than new drugs because safety is known. Still, 2026 brought a miss: Bylvay failed the phase 3 BOLD trial in biliary atresia.

Navtemadlin is the largest bet. Its supporting phase 1b/2 data came from 19 patients without a control arm. Hematology drugs reached approval from phase 1 23.9% of the time in the BIO/Informa/QLS study, and phase 3 programs overall reached filing 57.8% of the time. POIESIS reads out in 2027. Potravitug's next trial is phase 2/3, where base rates are lower.

The money

Ipsen is large and profitable, and oncology, at €2,196.9 million for nine months, is the biggest of its three units. Nine-month sales were €3,364.2 million, and the company now guides to about 23.0% sales growth at constant currency and a core operating margin around 39.0%. First-half core operating income was €844.9 million, free cash flow €651.7 million and net cash €1,004.9 million at June 30.

The deals were affordable. Ipsen paid $450 million upfront for Kartos with up to $1.3 billion in milestones, and €200 million upfront for Memo with total potential consideration above €700 million. Most of the contingent cost comes due only if the drugs succeed.

The risks

Somatuline is the main one. Ipsen's guidance assumes generic lanreotide enters in the fourth quarter of 2026. The core portfolio is growing 24.2%, which helps, but losing exclusivity on a large product usually cuts sales quickly.

Legal risk is rising around corabotase. Galderma opened two further arbitrations in October 2026. Ipsen won an earlier ruling in January but says it cannot predict the outcome of the new cases.

Clinical risk is concentrated in acquired assets whose data are early or small. Potravitug's evidence is a 95-patient phase 2 trial in which 24.4% of treated patients reached undetectable viral DNA by week 38 versus 13.0% on placebo, a real but modest difference. Neither asset has yet shown the survival or graft outcomes regulators ultimately weigh.

Integration is a further demand. Ipsen closed two acquisitions within about a month, Memo on July 22 and Kartos on August 21, while also preparing migraine and primary biliary cholangitis filings.

Our read

Ipsen in 2026 has done what investors asked of it: grown the business beyond Somatuline and replaced its pipeline with assets that could launch in the late 2020s. Two guidance raises and a rising margin show the commercial engine is working. The next phase is harder. Generic lanreotide will hit in the coming quarters, Galderma has escalated its dispute, and the company's biggest new bet, navtemadlin, rests on 19 patients until POIESIS reports. The February 11, 2027 results should show how much of the growth survives the first months of Somatuline generics.